Cerebral cortex dose sparing for glioblastoma patients: IMRT versus robust treatment planning

BACKGROUND: To date, patients with glioblastoma still have a bad median overall survival rate despite radiation dose-escalation and combined modality treatment. Neurocognitive decline is a crucial adverse event which may be linked to high doses to the cortex. In a planning study, we investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Exeli, Ann-Katrin, Kellner, Daniel, Exeli, Lukas, Steininger, Phil, Wolf, Frank, Sedlmayer, Felix, Deutschmann, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801703/
https://www.ncbi.nlm.nih.gov/pubmed/29409516
http://dx.doi.org/10.1186/s13014-018-0953-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801703/
https://www.ncbi.nlm.nih.gov/pubmed/29409516
http://dx.doi.org/10.1186/s13014-018-0953-x

Ejemplares similares